Updates are available Correction dated 2020-12-18
Click to view Correction: https://doi.org/10.1038/s42255-020-00335-x
-
Authors
Lin, Yu-Hsi http://orcid.org/0000-0001-5763-1530
Satani, Nikunj http://orcid.org/0000-0003-3908-3731
Hammoudi, Naima
Yan, Victoria C.
Barekatain, Yasaman
Khadka, Sunada
Ackroyd, Jeffrey J.
Georgiou, Dimitra K.
Pham, Cong-Dat http://orcid.org/0000-0002-0747-4343
Arthur, Kenisha
Maxwell, David http://orcid.org/0000-0001-5926-8501
Peng, Zhenghong
Leonard, Paul G.
Czako, Barbara
Pisaneschi, Federica http://orcid.org/0000-0002-1989-4417
Mandal, Pijus
Sun, Yuting http://orcid.org/0000-0002-0975-7902
Zielinski, Rafal
Pando, Susana Castro
Wang, Xiaobo http://orcid.org/0000-0003-0397-919X
Tran, Theresa
Xu, Quanyu
Wu, Qi
Jiang, Yongying
Kang, Zhijun
Asara, John M.
Priebe, Waldemar
Bornmann, William
Marszalek, Joseph R.
DePinho, Ronald A.
Muller, Florian L.
-
Funding
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RP140612)
American Chemical Society (RSG-15-145-01-CDD)
Andrew Sabin Family Foundation
- License Information
-
More Information
Article History
Received: 16 January 2020
Accepted: 15 October 2020
First Online: 23 November 2020
Change Date: 18 December 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: F.L.M. and R.A.D. are inventors on a patent covering the concept of targeting ENO1-deleted tumours with inhibitors of ENO2 (US patent 9,452,182 B2). F.L.M., R.A.D., D.M., W.B., Y.-H.L, N.S., Z.P., B.C. and F.P. are inventors on a patent application for the use of enolase inhibitors for the treatment of ENO1-deleted tumours (US patent 10,363,261 B2). V.C.Y, C-D.P and FLM are inventors on a patent application describing the synthesis and utility of novel prodrug inhibitors of enolase US 62/797,315 (filed 27 January 2019) R.A.D. is founder, director and/or advisor of Tvardi Therapeutics, Asylia Therapeutics and Stellanova Therapeutics, and the focus of these companies is not related to the content of this manuscript.
